Press Releases

News Release - March 15, 2018
AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1

News Release - October 18, 2017
AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting

News Release - September 25, 2017
AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study

News Release - July 20, 2017
AMO Pharma Enters into Development and License Agreement with Numedicus Limited for Rett Syndrome Program

In the Media

AMO Pharma Advancing Ultra-Rare Program on Back of Phase IIb Data - April 10, 2018


Early Clinical Trials of AMO-02 Show Promise in Congenital and Childhood Myotonic Dystrophy Type 1 - March 23, 2018


Companies pair up to take Rett Syndrome program into clinic - July 20, 2017


News of Note—Trevena CMO exit; AMO deal; Kala IPO; AliveCor-Mayo pact - July 20, 2017

FDA Gives Fast Track Status to Potential Therapy for Congenital Myotonic Dystrophy - June 1, 2017

AMO Pharma receives FDA Fast Track Status - May 30, 2017


FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford - May 30, 2017


AMO Pharma Addresses Rare Childhood Disease - May 22, 2017


Ranedis and AMO Partner to Develop HDAC Inhibitor for Rare Genetic Diseases - March 14, 2017


AMO Pharma and Ranedis target rare genetic diseases in RND-001 deal - March 14, 2017


Wayne-Based AMO Pharma Raises $25 Million - October 1, 2015


Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma - October 1, 2015

Stay updated about AMO! Enter your information here to receive updates about AMO Pharma via email:

To unsubscribe from all AMO Pharma communications, please click here.